Ethosomal Emulgel: A Review

Abstract

Ethosomal emulgels are advanced hybrid drug delivery systems developed to overcome the limitations of conventional topical and transdermal formulations. These systems combine ethanol-rich, highly deformable ethosomal vesicles with a semi-solid emulgel matrix, resulting in enhanced skin permeation, controlled drug release, improved stability, and better patient compliance. Ethanol plays a critical role by fluidizing stratum corneum lipids and increasing vesicular flexibility, thereby facilitating deeper penetration of both hydrophilic and lipophilic drugs. Incorporation of ethosomes into an emulgel base improves viscosity, prolongs residence time on the skin, and minimizes vesicle aggregation and drug leakage. This review highlights the rationale, composition, preparation methods, penetration mechanisms, evaluation parameters, advantages, limitations, and therapeutic applications of ethosomal emulgels. Preclinical studies demonstrate superior drug permeation, sustained release, and enhanced therapeutic efficacy compared with conventional gels and emulsions. Despite challenges such as ethanol-induced irritation and limited clinical data, ethosomal emulgels represent a promising platform for non-invasive topical and transdermal drug delivery..

Keywords

Ethosomal emulgel; Nanovesicular drug delivery; Topical and transdermal delivery; Skin permeation enhancement; Controlled drug release

Introduction

 

Mechanism of Skin Penetration of Ethosomal Emulgel

The superior skin penetration observed with ethosomal emulgels is attributed to a synergistic, multi-mechanistic process involving the combined effects of ethanol, highly flexible ethosomal vesicles, and the emulgel matrix ^1,2. In contrast to conventional topical formulations, ethosomal emulgels can traverse the stratum corneum barrier via both biochemical and physical mechanisms, resulting in enhanced dermal and transdermal drug delivery ^1,35.

1. Barrier Function of the Stratum Corneum

The stratum corneum, which constitutes the outermost layer of the skin, is formed by corneocytes embedded within a lipid matrix predominantly composed of ceramides, cholesterol, and free fatty acids ⁵. This well-organized lipid arrangement serves as the principal barrier to drug penetration, especially for hydrophilic and high-molecular-weight molecules ⁶. Traditional gels and creams are often inadequate in overcoming this barrier, leading to suboptimal drug permeation ^5,7.

2. Role of Ethanol in Skin Penetration

Ethanol, present at relatively high concentrations 20-45% in ethosomal formulations, plays a pivotal role in enhancing transdermal drug delivery ¹. It interacts with the intercellular lipids of the stratum corneum, reducing lipid crystallinity and increasing membrane fluidity ^5,8. By disrupting hydrogen bonding within the lipid bilayers, ethanol generates transient pores in the stratum corneum ^5,8, while simultaneously enhancing the solubility of drugs and their partitioning into the skin layers ^2,4. This ethanol mediated lipid fluidization weakens the skin barrier, thereby promoting deeper penetration of both ethosomal vesicles and their encapsulated therapeutic agents ^1,32.

3. Role of Flexible Ethosomal Vesicles

Ethosomes are soft, highly deformable vesicles, exhibiting significant elasticity due to the incorporation of ethanol within their bilayers ¹. Following ethanol-mediated disruption of the stratum corneum lipids, ethosomal vesicles penetrate the skin through multiple mechanisms:

• Intercellular pathway: Ethosomes traverse the lipid channels between corneocytes ^5,32.
• Vesicular transport: Intact ethosomes migrate into deeper skin layers while retaining their encapsulated drug ^2,32.
• Fusion mechanism: The phospholipid bilayers of ethosomes may fuse with skin lipids, facilitating direct release of the drug into deeper layers ¹.

The small size and remarkable flexibility of ethosomes enable them to penetrate significantly deeper than conventional liposomes, reaching the viable epidermis and, in some cases, the dermis ³⁴.

4. Contribution of the Emulgel Matrix

The emulgel component of the formulation further promotes skin penetration through several indirect mechanisms. Its increased viscosity prolongs residence time on the skin surface, facilitating extended interaction between ethanol and stratum corneum lipids ^7,10. The gel network also enables controlled release of both ethosomes and the encapsulated drug, maintaining a favorable concentration gradient across the skin layers ^6,10. Additionally, the occlusive properties of the emulgel enhance skin hydration, which loosens the stratum corneum structure and further improves permeability ^7,10. Collectively, the emulgel functions as a supportive carrier, optimizing the overall penetration efficiency of ethosomal vesicles ^7,10.

5. Combined Synergistic Mechanism

The overall mechanism of skin penetration by ethosomal emulgel can be summarized as follows:

• Ethanol disrupts and fluidizes the lipids of the stratum corneum ^1,2.
• Flexible ethosomal vesicles traverse the loosened lipid channels ^2,5.
• Vesicles either fuse with skin lipids or release the encapsulated drug into deeper
  layers ^1,5.
• The emulgel matrix prolongs residence time and modulates drug release ^6,10.

This synergistic combination of ethanol, deformable vesicles, and emulgel matrix significantly enhances drug permeation and retention within skin tissues, outperforming conventional gels, emulsions, or ethosomal suspensions alone³⁵

Therapeutic Implications

Owing to their enhanced penetration capabilities, ethosomal emulgels are particularly suitable for:

• Localized dermal therapy ^2,7
• Transdermal systemic delivery ¹
• Administration of poorly permeable drugs ^2,4
• Sustained and controlled topical treatments ^6,10

Method of Preparation of Ethosomal Emulgel

The preparation of an ethosomal emulgel involves a three-step process, namely:
(i) Preparation of ethosomal vesicles

(ii)  Preparation of the Emulgel base, and

(iii)  Incorporation of ethosomes into the emulgel

This stepwise approach ensures the structural integrity of ethosomes and uniform distribution within the semi-solid base.

Preparation of Ethosomal Vesicles

Ethosomes are most commonly prepared using the cold method, which is widely preferred due to its operational simplicity and suitability for encapsulating thermolabile drugs . In this approach, phospholipids such as soya lecithin or phosphatidylcholine are dissolved in ethanol under continuous magnetic stirring at room temperature¹ . The drug is incorporated either into the ethanolic phase or the aqueous phase, depending on its solubility characteristics ²⁰.

Purified water is subsequently added slowly to the ethanolic lipid solution under continuous stirring, leading to the spontaneous formation of ethosomal vesicles ¹. The resulting dispersion is stirred until a uniform and homogeneous ethosomal suspension is achieved. When necessary, vesicle size can be further reduced and standardized using techniques such as sonication or extrusion ^1,20.

Preparation of Emulgel Base

The emulgel base is prepared by first formulating an oil-in-water (O/W) emulsion, followed by its incorporation into a gel base ³².

Preparation of Emulsion

The oil phase, consisting of components such as liquid paraffin or isopropyl myristate, and the aqueous phase containing purified water are prepared separately ^32,10. Lipophilic surfactants (e.g., Span 80) are incorporated into the oil phase, whereas hydrophilic surfactants such as Tween 80, along with suitable preservatives, are added to the aqueous phase ^32,10. Both phases are heated independently to 70-75 °C and subsequently combined under continuous stirring, resulting in the formation of a stable oil-in-water (O/W) emulsion ¹⁰.

Preparation of Gel Base

Gelling agents such as Carbopol 934 or Carbopol 940 are dispersed in purified water under continuous stirring and allowed to hydrate completely to form a uniform dispersion ³⁷. The pH of the hydrated polymer system is subsequently adjusted using triethanolamine, resulting in the formation of a clear and homogeneous gel base ³⁷. The previously prepared emulsion is then gradually incorporated into the gel base with gentle stirring, leading to the formation of the emulgel ²¹.

Incorporation of Ethosomes into Emulgel

The prepared ethosomal suspension is slowly incorporated into the emulgel base under gentle and uniform stirring to minimize vesicle disruption ^2,7. This process is performed at room temperature to preserve the structural integrity of the ethosomal vesicles ^4,6. The resulting ethosomal emulgel should exhibit a smooth, homogeneous texture and be free from air entrapment ^32,11. Following incorporation, the formulation is allowed to equilibrate and is subsequently stored in appropriate containers for further evaluation and characterization ¹².

Significance of the Preparation Method

This preparation approach ensures the preservation of ethosomal vesicle integrity ^1,4 and promotes uniform distribution of vesicles throughout the emulgel matrix ^2,32. Additionally, it enhances formulation stability and prolongs residence time on the skin surface ²¹, while simultaneously improving drug permeation and enabling controlled release of the encapsulated drug ^1,21.

Evaluation Parameters of Ethosomal Emulgel

Evaluation of ethosomal emulgel formulations is crucial to ensure their physicochemical quality, vesicular integrity, skin compatibility, stability, and therapeutic efficacy¹. Comprehensive characterization enables the establishment of the advantages of ethosomal emulgels over conventional topical formulations, particularly with respect to enhanced skin permeation and controlled drug release behavior ^1,20.

1. Vesicular Characterization

1.1 Vesicle Size and Polydispersity Index (PDI)

Vesicle size is a critical parameter influencing the skin penetration efficiency and physical stability of ethosomal vesicles ^1,5. Smaller vesicles with a narrow size distribution facilitate deeper penetration into the stratum corneum and improve drug delivery to viable skin layers ^6,7. The polydispersity index (PDI) reflects the uniformity of vesicle size distribution, with lower PDI values indicating greater homogeneity of the formulation ^5,8. Vesicle size and PDI are commonly determined using dynamic light scattering (DLS) techniques ⁸.

1.2  Zeta Potential

Zeta potential indicates the surface charge and electrostatic stability of ethosomal vesicles ^32,5. Higher absolute zeta potential values contribute to enhanced formulation stability by preventing vesicle aggregation through electrostatic repulsion ^32,10. Zeta potential measurements are generally performed using electrophoretic light scattering methods ⁸.

1.3  Entrapment Efficiency

Entrapment efficiency represents the proportion of drug encapsulated within the ethosomal vesicles relative to the total drug content ¹. A high entrapment efficiency ensures effective drug loading and supports sustained drug release from the formulation. It is typically evaluated by separating the free drug from the vesicular system using techniques such as centrifugation, ultrafiltration, or dialysis, followed by quantitative drug analysis ^1,20.

2. Physicochemical Evaluation of Ethosomal Emulgel

2.1 Appearance and Homogeneity

The ethosomal emulgel is visually inspected for parameters such as color, consistency, phase separation, grittiness, and overall homogeneity ^13,29. A smooth, uniform appearance indicates proper incorporation and even distribution of ethosomal vesicles within the emulgel matrix ^29,15.

2.2  pH Measurement

pH is an important parameter affecting skin compatibility and formulation stability ^29,16. Ideally, the pH of ethosomal emulgels should be maintained within the range of 5.0-7.0 to minimize the risk of skin irritation and ensure patient safety ^16,17. The pH is measured using a calibrated digital pH meter ¹⁷.

2.3 Drug Content Uniformity

Drug content uniformity confirms the even distribution of the drug throughout the emulgel matrix, which is essential for dose accuracy and consistent therapeutic performance ^33,29. This parameter is determined by dissolving a known quantity of formulation in a suitable solvent, followed by analysis using UV-visible spectrophotometry or high-performance liquid chromatography (HPLC) ^33,18.

3. Rheological and Mechanical Properties

3.1 Viscosity and Rheological Behavior

Viscosity significantly influences the spreadability, extrudability, and residence time of the emulgel on the skin surface ^13,19. Most ethosomal emulgels exhibit pseudoplastic (shear-thinning) behavior, which allows ease of application under shear stress while ensuring adequate retention at the site of application ^19,20. Viscosity measurements are commonly carried out using Brookfield or cone-and-plate viscometers ²⁰.

3.2  Spreadability

Spreadability reflects the ease of application and overall patient acceptability of the formulation ^14,21. Adequate spreadability ensures uniform distribution of the drug over the skin surface, thereby enhancing therapeutic effectiveness ^21,22. It is typically assessed by measuring the distance or time required for the formulation to spread between two glass slides under a specified load ²².

3.3  Extrudability

Extrudability indicates the ease with which the emulgel can be expelled from collapsible tubes, directly influencing user convenience and compliance ^21,23. Satisfactory extrudability ensures consistent dosing during topical application ²³.

4. In Vitro Drug Release Studies

In vitro drug release studies are performed to evaluate the release kinetics of the drug from the ethosomal emulgel formulation ^33,24. These studies are commonly conducted using Franz diffusion cells equipped with synthetic or semi-permeable membranes ^24,25. The resulting release profiles provide valuable insight into the sustained and controlled release characteristics of the formulation ^25,26.

5. Ex Vivo Skin Permeation Studies

Ex vivo skin permeation studies using excised animal or human skin are carried out to assess the penetration and retention potential of ethosomal emulgels ^1,4. These studies consistently demonstrate significantly higher drug flux and enhanced skin deposition when compared with conventional gels and emulsions ^6,27.

6. Skin Irritation and Sensitivity Studies

Skin irritation studies are conducted to evaluate the safety of ethosomal emulgels intended for topical application ^16,28. The formulation is assessed for signs of erythema and edema using suitable animal models or validated alternative in vitro methods ^28,29. A non-irritant profile confirms the suitability of the formulation for dermal use ²⁹.

7. Stability Studies

Stability studies are performed to assess the physical, chemical, and microbiological stability of ethosomal emulgel formulations under various storage conditions ^11,30. Parameters such as vesicle size, pH, viscosity, drug content, and physical appearance are monitored over time ^30,31. These studies are generally conducted in accordance with International Council for Harmonisation (ICH) stability guidelines ³¹.

Advantages of Ethosomal Emulgel

Ethosomal emulgels are advanced topical and transdermal delivery systems that combine the penetration-enhancing ability of ethosomes with the favorable properties of gel-based formulations, offering clear advantages over conventional topical systems ^1,20,35.

1. Enhanced skin penetration: It is achieved through the synergistic action of ethanol and deformable vesicles, which significantly improves drug permeation across the stratum corneum ^1,4,7.

2. Improved drug solubility and entrapment: High ethanol content enhances solubility and drug loading for both hydrophilic and lipophilic drugs ^1,8,32.

3. Controlled and sustained release: The emulgel matrix provides prolonged and regulated drug release, reducing dosing frequency ^10,33.

4. Prolonged skin residence time: High viscosity and adhesiveness ensure extended contact with the skin, enhancing absorption ^10,13,29.

5. Improved vesicle stability: Gel incorporation minimizes vesicle aggregation and ethanol loss, maintaining vesicular integrity ^1,15,16.

6. Better patient compliance: Non-greasy texture and good spreadability improve cosmetic acceptability and adherence ^10,17,18.

7. Formulation versatility: Suitable for a wide range of drugs and applicable for both dermal and transdermal delivery ^2,19.

8. Reduced systemic side effects: Enhanced local targeting lowers systemic exposure and improves safety ^20,21.

9. Bypass of first-pass metabolism: Transdermal delivery improves bioavailability of drugs subject to hepatic metabolism ^22,23.

10. Cost-effective and scalable: Simple, reproducible preparation methods support industrial scale-up and commercialization^32,16,24.

Disadvantages of Ethosomal Emulgel

1. Skin irritation and sensitization: High ethanol content may cause skin dryness, erythema, irritation, or burning sensations, especially with repeated use or in sensitive individuals, due to disruption of the stratum corneum lipid barrier ⁶.

2. Unsuitability for irritant drugs: Ethanol-induced barrier disruption can enhance drug-related skin toxicity, limiting the use of ethosomal emulgels for inherently irritant or highly potent drugs during long-term therapy ^7,32.

3. Vesicle instability: Ethosomal vesicles are prone to aggregation, fusion, and size variation during storage, which may affect drug release and permeation; ethanol evaporation can further compromise vesicle integrity ^10,33.

4. Limited drug loading capacity: Structural limitations of ethosomes may restrict drug loading, particularly for macromolecules and highly hydrophilic drugs such as peptides and proteins^2,13,29.

5. Formulation and optimization complexity: Precise optimization of ethanol concentration, phospholipid content, surfactant ratio, and gel viscosity is required, as minor changes can significantly affect stability and permeation performance ^15,17.

6. Scale-up and manufacturing challenges: Large-scale production is difficult due to vesicle sensitivity to processing conditions, potentially increasing manufacturing costs and limiting industrial scalability ^33,18,19.

7. Limited clinical and regulatory data: Insufficient large-scale clinical studies and the absence of specific regulatory guidelines may delay clinical translation and commercialization ^1,20,21.

8. Short shelf life: Ethanol volatility and vesicular degradation during storage, particularly under high temperature and humidity, may reduce shelf life and require specialized packaging ^11,22,23.

9. Risk of drug leakage: Vesicle destabilization during storage or after incorporation into the emulgel base may lead to drug leakage and dose inconsistency ^10,24,25.

10. Higher formulation cost: The use of high-purity phospholipids, ethanol, and specialized processing techniques increases formulation cost compared with conventional topical gels or creams ^19,26,27.

Applications of Ethosomal Emulgel

Ethosomal emulgels have emerged as a versatile and effective platform for topical and transdermal drug delivery, primarily due to their superior skin permeation capability, controlled drug release characteristics, and enhanced patient compliance ^1,2.

1. Topical Treatment of Inflammatory and Pain Conditions

Ethosomal emulgels have been extensively investigated for the topical delivery of non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics, providing enhanced skin penetration and prolonged drug retention at the site of action ⁴. The ability of ethosomal vesicles to promote deeper drug deposition within inflamed tissues leads to improved therapeutic efficacy while minimizing systemic exposure and associated adverse effects compared with conventional gels and creams ^4,5.

2. Dermatological and Cosmetic Applications

Ethosomal emulgels are widely utilized for the delivery of dermatological agents, including corticosteroids, antifungal agents, anti-acne drugs, and depigmenting agents ^6,7. Enhanced penetration of ethosomal carriers facilitates greater drug accumulation within the epidermal and dermal layers, making them particularly effective in the management of chronic skin disorders such as psoriasis, eczema, and acne vulgaris ^7,8. In cosmetic applications, ethosomal emulgels are employed for the delivery of antioxidants, vitamins, and anti-aging agents, enabling deeper skin nourishment and prolonged cosmetic benefits ^32,10.

3. Transdermal Systemic Drug Delivery

Ethosomal emulgels are suitable for the transdermal administration of drugs intended for systemic action, as ethosomes are capable of transporting therapeutic agents across the stratum corneum into the systemic circulation ^1,11. This route of administration helps bypass hepatic first-pass metabolism, maintain stable plasma drug concentrations, and reduce dosing frequency ^11,33.

4. Delivery of Poorly Permeable Drugs

Ethosomal emulgels are particularly advantageous for drugs exhibiting poor skin permeability, low bioavailability, or unfavorable physicochemical properties ^2,13. The combined effect of ethanol-induced lipid fluidization and the flexibility of vesicular membranes enhance drug partitioning into skin layers, thereby improving therapeutic outcomes ^13,29.

5. Antimicrobial and Antifungal Therapy

Ethosomal emulgels have demonstrated enhanced efficacy in the topical delivery of antimicrobial and antifungal agents by increasing drug penetration into deeper skin layers and infected tissues ^6,15. This improved delivery results in higher local drug concentrations and more effective eradication of microbial infections compared with conventional topical formulations ^15,16.

6. Delivery of Hormones and Peptides

Ethosomal emulgels have also been explored for the transdermal delivery of hormones and peptide-based drugs, owing to their ability to enhance the permeation of macromolecules across the skin barrier ^33,17. These systems offer a non-invasive alternative to injectable formulations and significantly improve patient compliance ^17,18.

7. Targeted Localized Therapy

Ethosomal emulgels are effective in achieving targeted localized drug delivery to the skin and underlying tissues, thereby minimizing systemic exposure and reducing the risk of adverse effects ¹⁹. This characteristic is particularly beneficial for chronic topical therapies that require prolonged treatment durations ^19,20.

8.  Sustained and Controlled Drug Release

The emulgel matrix provides a controlled release environment, while ethosomal vesicles facilitate deeper drug penetration, making ethosomal emulgels suitable for sustained topical and transdermal therapy ^21,22. This dual functionality enhances therapeutic efficacy and reduces dosing frequency ^22,23.

9. Wound Healing and Skin Regeneration

Ethosomal emulgels are being investigated for wound healing applications due to their ability to deliver antimicrobial, anti-inflammatory, and growth-promoting agents directly to the wound site ^24,25. Improved drug penetration and prolonged residence time at the wound surface contribute to accelerated wound closure and enhanced tissue regeneration ^25,26.

10. Vaccines and Immunological Applications

Recent studies indicate the potential application of ethosomal emulgels in transcutaneous immunization, wherein antigens are delivered through the skin to elicit immune responses ^27,28. This strategy offers a painless, needle-free alternative to conventional vaccination methods and may improve patient acceptance and compliance ^28,29.

CONCLUSION

Ethosomal emulgels represent a significant advancement in topical and transdermal drug delivery by synergistically combining the penetration-enhancing properties of ethanol-rich, deformable ethosomal vesicles with the stability and patient-friendly characteristics of emulgel systems. This hybrid approach effectively addresses major limitations of conventional topical formulations, including poor stratum corneum permeability, limited residence time, and inconsistent drug release. The ethanol-mediated fluidization of skin lipids, coupled with vesicular deformability, enables deeper dermal penetration and improved bioavailability of both hydrophilic and lipophilic drugs, while the emulgel matrix ensures controlled release, enhanced stability, and prolonged skin contact. Comprehensive formulation strategies and evaluation parameters discussed in this review highlight the versatility and robustness of ethosomal emulgels across a wide range of therapeutic applications, including dermatological, antimicrobial, anti-inflammatory, and transdermal systemic therapies. Despite challenges related to ethanol-induced irritation, formulation complexity, and limited clinical validation, ongoing advancements in nanotechnology and formulation optimization continue to strengthen their translational potential. Overall, ethosomal emulgels emerge as promising, non-invasive delivery platforms capable of improving therapeutic outcomes and patient compliance, warranting further clinical investigation and industrial development.

 

 

REFERENCES

1. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes-novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. Journal of controlled release. 2000 Apr 3;65(3):403-18.
2. Touitou E, inventor. Compositions for applying active substances to or through the skin. United States patent US 5,540,934. 1996 Jul 30.
3.  Allen LV, Popovich NG, Ansel HC. Ansel’s pharmaceutical calculations. 15th ed.   Philadelphia: Wolters Kluwer; 2020.
4. Kehinde EO, Akrutiben S, Patel J. Revolutionary Approach towards Transdermal Drug Delivery: Ethosomal Gels. J. Pharm. Res. Int. [Internet]. 2021 Apr. 23 [cited 2026 Jan. 26];33(25B):35-43. Available from: https://journaljpri.com/index.php/JPRI/article/view/2282

5. Kyriakoudi A, Spanidi E, Mourtzinos I, Gardikis K. Innovative Delivery Systems Loaded with Plant Bioactive Ingredients: Formulation Approaches and Applications. Plants 2021, 10, 1238 [Internet]. 2021
6. Gaber DA, Alsubaiyel AM, Alabdulrahim AK, Alharbi HZ, Aldubaikhy RM, Alharbi RS, Albishr WK, Mohamed HA. Nano-emulsion-based gel for topical delivery of an anti-inflammatory drug: in vitro and in vivo evaluation. Drug Des Devel Ther. 2023;17:1435–1451. doi:10.2147/DDDT.S407475. PMID:37216175; PMCID: PMC10198277.
7.  Donthi MR, Munnangi SR, Krishna KV, Saha RN, Singhvi G, Dubey SK. Nanoemulgel: A novel nano carrier as a tool for topical drug delivery. Pharmaceutics. 2023;15(1):164. doi:10.3390/pharmaceutics15010164. PMID:36678794; PMCID: PMC9863395.

8. Moghaddam AA, Aqil M, Ahmad FJ, Ali MM, Sultana Y, Ali A. Nanoethosomes mediated transdermal delivery of vinpocetine for management of Alzheimer’s disease. Drug delivery. 2015 Nov 17;22(8):1018-26.
9. Rowe RC, Sheskey PJ, Weller PJ, editors. Handbook of pharmaceutical excipients. London: Pharmaceutical press; 2006 Jan 30.

10. Touitou E, Natsheh H. Topical administration of drugs incorporated in carriers containing phospholipid soft vesicles for the treatment of skin medical conditions. Pharmaceutics. 2021;13(12):2129. doi:10.3390/pharmaceutics13122129. PMID:34959410; PMCID:PMC8706871.
11. Dhurve R, Mishra A. Formulation and evaluation of ethosomal gel of fluconazole for topical drug delivery. 2019.
12. Williams AC, Barry BW. Penetration enhancers. Advanced drug delivery reviews. 2012 Dec 1;64:128-37.
13. Kiriyama A, Honbo A, Iga K. Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans. International journal of pharmaceutics. 2008 Feb 12;349(1-2):53-60.
14. Tadros TF. Emulsion formation, stability, and rheology. Emulsion formation and stability. 2013 Jan 16:1-75.

15. Indora N, Kaushik D. Design, development and evaluation of ethosomal gel of fluconazole for topical fungal infection. Int J Eng Sci Invention Res Dev. 2015 Feb;1(8):280–286.
16. Guideline IH. Stability testing of new drug substances and products. Q1A (R2), current step. 2003 Feb;4(1-24).
17.  Mahmood S, Mandal UK, Chatterjee B. Transdermal delivery of raloxifene HCl via ethosomal system: formulation, advanced characterizations and pharmacokinetic evaluation. Int J Pharm. 2018 May 5;542(1–2):36–46. doi:10.1016/j.ijpharm.2018.02.044. PMID:29501737.

18. Uchechi O, Ogbonna JD, Attama AA. Nanoparticles for dermal and transdermal drug delivery. Application of nanotechnology in drug delivery. 2014 Jul 25;4:193-227.
19. Ni?escu DA, P?unescu H, Costescu M, Ni?escu B, Coman L, Fulga I, Coman OA. Novel Research Regarding Topical Use of Diclofenac in Dermatology-Non-Clinical and Clinical Data. Scientia Pharmaceutica. 2025 Jul 30;93(3):34.
20. Bhalaria MK, Naik S, Misra AN. Ethosomes: a novel delivery system for antifungal drugs in the treatment of topical fungal diseases. Indian J Exp Biol. 2009 May;47(5):368–375. PMID:19579803.

21. Gaikwad N, Aher R, Bagul M, Sharma Y, Sonawane D, Patil D. A comprehensive review on emulgel as a topical drug delivery system. Int J Pharm Sci. 2024;2(5):1398–1405. doi:10.5281/zenodo.11317649.
22. Yadav SK, Mishra MK, Tiwari A, Shukla A. Emulgel: A new approach for enhanced topical drug delivery. Int J Curr Pharm Res. 2016 Dec;9(1):15-9.
23. Phad AR, Nandgude TD, Ganapathy RS. Emulgel: a comprehensive review for topical delivery of hydrophobic drugs. Asian J Pharm. 2018;12(2 Suppl):S382–S388.

24. Giuliano E, Paolino D, Fresta M, Cosco D. Mucosal applications of poloxamer 407-based hydrogels: An overview. Pharmaceutics. 2018 Sep 12;10(3):159.
25. Donthi MR, Munnangi SR, Krishna KV, Saha RN, Singhvi G, Dubey SK. Nanoemulgel: a novel nano carrier as a tool for topical drug delivery. Pharmaceutics. 2023 Jan 3;15(1):164.
26. Kute SB, Saudagar RB. Emulsified gel: a novel approach for delivery of hydrophobic        drugs-an overview. J Adv Pharm Educ Res. 2013;3(4):368–376.

27. Keservani RK, Kesharwani RK, Sharma AK, editors. Advances in novel formulations for drug delivery. John Wiley & Sons; 2023 Mar 14.
28. Nayak AK, Hasnain MS, Aminabhavi TM, Torchilin VP, editors. Systems of nanovesicular drug delivery. Academic Press; 2022 Jul 16.
29. Prausnitz MR, Langer R. Transdermal drug delivery. Nature biotechnology. 2008  Nov;26(11):1261-8.
30. Ethosome. Wikipedia, The Free Encyclopedia [Internet]. 2024 Mar 5 [cited 2026 Feb5].Available from: https://en.wikipedia.org/w/index.php?title=Ethosome&oldid=1211975596
31. ICH Expert Working Group. Q1A(R2): Stability testing of new drug substances and products. Geneva: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2003 Feb. Report No.: ICH-Q1A(R2).
32. Verma DD, Fahr A. Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporin A. Journal of controlled release. 2004 May 31;97(1):55-66.4.
33. Barry BW. Breaching the skin's barrier to drugs. Nature biotechnology. 2004 Feb    1;22(2):165-7.
34. Touitou E, Godin B, Weiss C. Enhanced delivery of drugs into and across the skin by ethosomal carriers. Drug development research. 2000 Jul;50(3?4):406-15.
35. Ascenso A, Raposo S, Batista C, Cardoso P, Mendes T, Praça FSG, Bentley MVLB, Simões S. Development, characterization, and skin delivery studies of related ultradeformable vesicles: transfersomes, ethosomes, and transethosomes. Int J Nanomedicine. 2015;10:5837–5851. doi:10.2147/IJN.S86186.
36. Kumar L, Verma R. In vitro evaluation of topical gel prepared using natural polymer. International journal of drug delivery. 2010 Jan 1;2(1):58-63.
37. Jain S, Patel N, Madan P. Formulation and evaluation of topical gel systems. Asian J Pharm Sci. 2011;6(3):141–148.
38. Tadros TF. Emulsion formation, stability, and rheology. Emulsion formation and stability. 2013 Jan 16:1-75.
39. Williams AC, Barry BW. Penetration enhancers. Advanced drug delivery reviews. 2012 Dec 1;64:128-37.
40. Rowe RC, Sheskey PJ, Weller PJ, editors. Handbook of pharmaceutical excipients. London: Pharmaceutical press; 2006 Jan 30.